Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2021

View Archived Issues

AFYX Therapeutics presents preclinical data on anti-TNF antibody delivery through adhesive patch

Small-molecule OXS-7417 shows in vivo AML antitumoral effects

StemSynergy Therapeutics patents N-myc proto-oncogene protein inhibitors

Salk Institute, Sanford Burnham Prebys describe new ULK1 inhibitors

New PIKfyve inhibitors identified at AcuraStem

Discovery of novel antibiotic class of tethered macrocyclic peptides

Novel virulence factor LasB inhibitors for the treatment of P. aeruginosa infections

HA-344 shows promise for treating cutaneous metastatic melanoma

PearlRiverBio patents mutant EGFR/HER2 inhibitors

STM-2457: a first-in-class METTL3 inhibitor with preclinical proof of concept in AML models

Flamingo and Ionis expand alliance to develop RNA-targeted therapies for oncology

GRC-39815 shows efficacy in models of smoke-induced COPD

Vitalgenics reports preclinical findings with excindogen in PDAC

Twist collaborates with Boehringer Ingelheim on antibody research programs

KG207-M, a novel bifunctional fusion protein as disease-modifying therapy for AD

Platinum(II)-NHC complex targeting vimentin inhibits tumor metastasis

fMLP receptor promotes inflammatory brain injury

At WCLC, early steps towards success against SCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...